Skip to main content

Biomonitor Acquires Irish Cell-based Assay Startup

NEW YORK (GenomeWeb News) – Danish firm Biomonitor said this week that it has acquired Irish startup Neutekbio, a cell-based assay and kit developer founded in 2003.
 
Several news agencies reported that the acquisition price was €7 million ($9 million). A Biomonitor spokesperson claimed that the amount is not accurate but declined to furnish additional details.
 
Biomonitor is a theranostics firm that is developing assays to measure biopharmaceutical drug levels and antibodies to these drugs. It said that the acquisition will complement its current offerings to physicians and clinics treating patients with multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.
 
Galway-based Neutekbio sells the assays and kits, which measure the biological activity of cytokines, under the tradename iLite. Biomonitor intends to retain Neutekbio’s R&D and manufacturing operations in Ireland and its ongoing collaboration with France’s Centre National de la Recherche Scientifique in Paris.
 
Biomonitor received financial support from Danish venture capital firm Sunstone Capital to complete the acquisition of Neutekbio.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.